Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 1/2015

01-01-2015 | Original Paper

The role of Pax5 in leukemia: diagnosis and prognosis significance

Authors: Mohammad Shahjahani, Fatemeh Norozi, Ahmad Ahmadzadeh, Saeid Shahrabi, Farzaneh Tavakoli, Ali Amin Asnafi, Najmaldin Saki

Published in: Medical Oncology | Issue 1/2015

Login to get access

Abstract

Pax5 transcription factor, also known as B-cell specific activator protein (BSAP), plays a dual role in the hematopoietic system. Pax5 expression is essential in B-cell precursors for normal differentiation and maturation of B-cells. On the other hand, it inhibits the differentiation and progress toward other lineages. The expression of this factor is involved in several aspects of B-cell differentiation, including commitment, immunoglobulin gene rearrangement, BCR signal transduction and B-cell survival, so that the deletion or inactivating mutations of Pax5 cause cell arrest in Pro-B-cell stage. In recent years, point mutations, deletions and various rearrangements in Pax5 gene have been reported in several types of human cancers. However, no clear relationship has been found between these aberrations and disease prognosis. Specific expression of Pax5 in B-cells can raise it as a marker for the diagnosis and differentiation of B-cell leukemias and lymphomas as well as account for remission or relapse. Extensive studies on Pax5 along with other genes and immunomarkers are necessary for decisive results in this regard.
Literature
1.
Zhou Y, You MJ, Young KH, Lin P, Lu G, Medeiros LJ, et al. Advances in the molecular pathobiology of B-lymphoblastic leukemia. Hum Pathol. 2012;43(9):1347–62.PubMedCrossRef
2.
Hütter G, Kaiser M, Neumann M, Mossner M, Nowak D, Baldus CD, et al. Epigenetic regulation of PAX5 expression in acute T-cell lymphoblastic leukemia. Leuk Res. 2011;35(5):614–9.PubMedCrossRef
3.
Nebral K, König M, Harder L, Siebert R, Haas OA, Strehl S. Identification of PML as novel PAX5 fusion partner in childhood acute lymphoblastic leukaemia. Br J Haematol. 2007;139(2):269–74.PubMedCrossRef
4.
Lang D, Powell SK, Plummer RS, Young KP, Ruggeri BA. PAX genes: roles in development, pathophysiology, and cancer. Biochem Pharmacol. 2007;73(1):1–14.PubMedCrossRef
5.
Bousquet M, Broccardo C, Quelen C, Meggetto F, Kuhlein E, Delsol G, et al. A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5. Blood. 2007;109(8):3417–23.PubMedCrossRef
6.
Medvedovic J, Ebert A, Tagoh H, Busslinger M. 5 Pax5: a master regulator of B cell development and leukemogenesis. Adv Immunol. 2011;111:179.PubMedCrossRef
7.
Iacobucci I, Lonetti A, Paoloni F, Papayannidis C, Ferrari A, Storlazzi CT, et al. The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. Haematologica. 2010:haematol. 2009. 020792.
8.
Souabni A, Jochum W, Busslinger M. Oncogenic role of Pax5 in the T-lymphoid lineage upon ectopic expression from the immunoglobulin heavy-chain locus. Blood. 2007;109(1):281–9.PubMedCrossRef
9.
Kee BL, Murre C. Transcription factor regulation of B lineage commitment. Curr Opin Immunol. 2001;13(2):180–5.PubMedCrossRef
10.
Torlakovic E, Slipicevic A, Robinson C, DeCoteau JF, Alfsen GC, Vyberg M, et al. Pax-5 expression in nonhematopoietic tissues. Am J Clin Pathol. 2006;126(5):798–804.PubMedCrossRef
11.
Usvasalo A, Ninomiya S, Räty R, Hollmén J, Saarinen-Pihkala UM, Elonen E, et al. Focal 9p instability in hematologic neoplasias revealed by comparative genomic hybridization and single-nucleotide polymorphism microarray analyses. Genes Chromosom Cancer. 2010;49(4):309–18.PubMed
12.
Souabni A, Cobaleda C, Schebesta M, Busslinger M. Pax5 promotes B lymphopoiesis and blocks T cell development by repressing Notch1. Immunity. 2002;17(6):781–93.PubMedCrossRef
13.
Revilla‐I‐Domingo R, Bilic I, Vilagos B, Tagoh H, Ebert A, Tamir IM, et al. The B‐cell identity factor Pax5 regulates distinct transcriptional programmes in early and late B lymphopoiesis. EMBO J. 2012;31(14):3130–46.
14.
Carotta S, Holmes M, Pridans C, Nutt SL. Pax5 maintains cellular identity by repressing gene expression throughout B cell differentiation. Cell Cycle-landes Biosci. 2006;5(21):2452.CrossRef
15.
Nutt SL, Morrison AM, Dörfler P, Rolink A, Busslinger M. Identification of BSAP (Pax-5) target genes in early B-cell development by loss-and gain-of-function experiments. EMBO J. 1998;17(8):2319–33.PubMedCentralPubMedCrossRef
16.
Nutt SL, Urbanek P, Rolink A, Busslinger M. Essential functions of Pax5 (BSAP) in pro-B cell development: difference between fetal and adult B lymphopoiesis and reduced V-to-DJ recombination at the IgH locus. Genes Dev. 1997;11(4):476–91.PubMedCrossRef
17.
18.
Tiacci E, Pileri S, Orleth A, Pacini R, Tabarrini A, Frenguelli F, et al. PAX5 expression in acute leukemias higher B-Lineage specificity than CD79a and selective association with t (8; 21)-acute myelogenous leukemia. Cancer Res. 2004;64(20):7399–404.PubMedCrossRef
19.
Schebesta A, McManus S, Salvagiotto G, Delogu A, Busslinger GA, Busslinger M. Transcription factor Pax5 activates the chromatin of key genes involved in B cell signaling, adhesion, migration, and immune function. Immunity. 2007;27(1):49–63.PubMedCrossRef
20.
Fuxa M, Skok J, Souabni A, Salvagiotto G, Roldan E, Busslinger M. Pax5 induces V-to-DJ rearrangements and locus contraction of the immunoglobulin heavy-chain gene. Genes Dev. 2004;18(4):411–22.PubMedCentralPubMedCrossRef
21.
Gonda H, Sugai M, Nambu Y, Katakai T, Agata Y, Mori KJ, et al. The balance between Pax5 and Id2 activities is the key to AID gene expression. J Exp Med. 2003;198(9):1427–37.PubMedCentralPubMedCrossRef
22.
Nera K-P, Kohonen P, Narvi E, Peippo A, Mustonen L, Terho P, et al. Loss of Pax5 promotes plasma cell differentiation. Immunity. 2006;24(3):283–93.PubMedCrossRef
23.
Forero RM, Hernández M, Hernández-Rivas JM. Genetics of acute lymphoblastic leukemia. In: Guenova M, Balatzenko, editors. Leukemia. InTech; 2013. ISBN 978-953-51-1127-6.
24.
Nebral K, Denk D, Attarbaschi A, König M, Mann G, Haas OA, et al. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia. 2008;23(1):134–43.PubMedCrossRef
25.
Mandel EM, Grosschedl R. Transcription control of early B cell differentiation. Curr Opin Immunol. 2010;22(2):161–7.PubMedCrossRef
26.
Strehl S, König M, Dworzak M, Kalwak K, Haas O. PAX5/ETV6 fusion defines cytogenetic entity dic (9; 12)(p13; p13). Leukemia. 2003;17(6):1121–3.PubMedCrossRef
27.
Familiades J, Bousquet M, Lafage-Pochitaloff M, Bene M, Beldjord K, De Vos J, et al. PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study. Leukemia. 2009;23(11):1989–98.PubMedCrossRef
28.
Fazio G, Biondi A, Cazzaniga G. The role of PAX5 in ALL. Nov Asp Acute Lymphoblastic Leuk Tech. 2011.
29.
Kawamata N, Ogawa S, Zimmermann M, Niebuhr B, Stocking C, Sanada M, et al. Cloning of genes involved in chromosomal translocations by high-resolution single nucleotide polymorphism genomic microarray. Proc Natl Acad Sci. 2008;105(33):11921–6.PubMedCentralPubMedCrossRef
30.
Hu H, Wang B, Borde M, Nardone J, Maika S, Allred L, et al. Foxp1 is an essential transcriptional regulator of B cell development. Nat Immunol. 2006;7(8):819.PubMedCrossRef
31.
Coyaud E, Struski S, Prade N, Familiades J, Eichner R, Quelen C, et al. Wide diversity of PAX5 alterations in B-ALL: a groupe francophone de cytogenetique hematologique study. Blood. 2010;115(15):3089–97.PubMedCrossRef
32.
Denk D, Bradtke J, König M, Strehl S. PAX5 fusion genes in t (7; 9)(q11. 2; p13) leukemia: a case report and review of the literature. Mol Cytogenet. 2014;7(1):13.PubMedCentralPubMedCrossRef
33.
Denk D, Nebral K, Bradtke J, Pass G, Möricke A, Attarbaschi A, et al. PAX5-AUTS2: a recurrent fusion gene in childhood B-cell precursor acute lymphoblastic leukemia. Leuk Res. 2012;36(8):e178–81.PubMedCentralPubMedCrossRef
34.
Moorman AV. The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia. Blood Rev. 2012;26(3):123–35.
35.
Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446(7137):758–64.PubMedCrossRef
36.
An Q, Wright SL, Konn ZJ, Matheson E, Minto L, Moorman AV, et al. Variable breakpoints target PAX5 in patients with dicentric chromosomes: a model for the basis of unbalanced translocations in cancer. Proc Natl Acad Sci. 2008;105(44):17050–4.PubMedCentralPubMedCrossRef
37.
Fortschegger K, Anderl S, Denk D, Strehl S. Functional heterogeneity of PAX5 chimeras reveals insight for leukemia development. Mol Cancer Res. 2014;12(4):595–606.PubMedCrossRef
38.
Mullighan C, Downing J. Genome-wide profiling of genetic alterations in acute lymphoblastic leukemia: recent insights and future directions. Leukemia. 2009;23(7):1209–18.PubMedCrossRef
39.
Portell CA, Wenzell CM, Advani AS. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol Adv Appl. 2013;5(Suppl 1):5.CrossRef
40.
Kang H, Roberts KG, Chen I-ML, Atlas SR, Bedrick EJ, Gastier-Foster JM, et al. Development and validation of a highly sensitive and specific gene expression classifier to prospectively screen and identify B-Precursor acute lymphoblastic leukemia (ALL) patients with a philadelphia chromosome-like (“Ph-like” or “BCR-ABL1-Like”) signature for therapeutic targeting and clinical intervention. Blood. 2013;122(21):826.
41.
Harder L, Eschenburg G, Zech A, Kriebitzsch N, Otto B, Streichert T, et al. Aberrant ZNF423 impedes B cell differentiation and is linked to adverse outcome of ETV6-RUNX1 negative B precursor acute lymphoblastic leukemia. J Exp Med. 2013;210(11):2289–304.PubMedCentralPubMedCrossRef
42.
Sarhadi VK, Lahti L, Scheinin I, Ellonen P, Kettunen E, Serra M, et al. Copy number alterations and neoplasia-specific mutations in MELK, PDCD1LG2, TLN1, and PAX5 at 9p in different neoplasias. Genes Chromosom Cancer. 2014;53(7):579–88.PubMedCrossRef
43.
44.
Sigvardsson M. Transcription factor dose links development to disease. Blood. 2012;120(18):3630–1.PubMedCrossRef
45.
Nasr MR, Rosenthal N, Syrbu S. Expression profiling of transcription factors in B-or T-Acute lymphoblastic leukemia/lymphoma and burkitt lymphoma usefulness of PAX5 immunostaining as Pan–Pre-B-Cell marker. Am J Clin Pathol. 2010;133(1):41–8.PubMedCrossRef
46.
Hutspardol S, Pakakasama S, Kanta K, Nuntakarn L, Anurathapan U, Sirachainan N, et al. Interphase-FISH screening for eight common rearrangements in pediatric B-cell precursor acute lymphoblastic leukemia. Int J Lab Hematol. 2013;35(4):406–15.PubMedCrossRef
47.
Desouki MM, Post GR, Cherry D, Lazarchick J. PAX-5: a valuable immunohistochemical marker in the differential diagnosis of lymphoid neoplasms. Clin Med Res. 2010;8(2):84–8.PubMedCentralPubMedCrossRef
48.
Heltemes-Harris LM, Willette MJ, Ramsey LB, Qiu YH, Neeley ES, Zhang N, et al. Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia. J Exp Med. 2011;208(6):1135–49.PubMedCentralPubMedCrossRef
49.
Bernt KM, Hunger SP. Current concepts in pediatric philadelphia chromosome-positive acute lymphoblastic leukemia. Fron Oncol. 2014.
50.
Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360(5):470–80.PubMedCentralPubMedCrossRef
51.
Slamova L, Starkova J, Fronkova E, Zaliova M, Reznickova L, van Delft FW, et al. CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage. Leukemia. 2014;28(3):609–20.
52.
Lundin C, Hjorth L, Behrendtz M, Nordgren A, Palmqvist L, Andersen MK, et al. High frequency of BTG1 deletions in acute lymphoblastic leukemia in children with Down syndrome. Genes Chromosom Cancer. 2012;51(2):196–206.PubMedCrossRef
53.
Kearney L, De Castro DG, Yeung J, Procter J, Horsley SW, Eguchi-Ishimae M, et al. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood. 2009;113(3):646–8.PubMedCrossRef
54.
Zhang H. The molecular mechanisms for maintenance of cancer stem cells in chronic myeloid leukemia: a dissertation. 2012.
55.
Zhang H, Peng C, Hu Y, Li H, Sheng Z, Chen Y, et al. The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells. Nat Genet. 2012;44(8):861–71.PubMedCentralPubMedCrossRef
56.
Ray D, Kwon SY, Ptasinska A, Bonifer C. Chronic growth factor receptor signaling and lineage inappropriate gene expression in AML: the polycomb connection. Cell Cycle. 2013;12(14):2159.PubMedCentralPubMedCrossRef
57.
Sadakane Y, Zaitsu M, Nishi M, Sugita K, Mizutani S, Matsuzaki A, et al. Expression and production of aberrant PAX5 with deletion of exon 8 in B-lineage acute lymphoblastic leukaemia of children. Br J Haematol. 2007;136(2):297–300.PubMedCrossRef
58.
Ray D, Kwon SY, Tagoh H, Heidenreich O, Ptasinska A, Bonifer C. Lineage-inappropriate PAX5 expression in t (8; 21) acute myeloid leukemia requires signaling-mediated abrogation of polycomb repression. Blood. 2013;122(5):759–69.PubMedCrossRef
59.
Zheng J, Dong S, Wang Q, Pan J, Chen S, Qiu H. Deletions and rearrangements of PAX5 gene in B-lineage acute lymphoblastic leukemia. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chin J Med Genet. 2013;30(5):549.
60.
Zakaria Z, Ahid MFM, Ismail A, Keoh TS, Nor NM, Kamaluddin NR, et al. Chromosomal aberrations in ETV6/RUNX1-positive childhood acute lymphoblastic leukemia using 244 K Oligonucleotide array comparative genomic hybridization. Mol Cytogenet. 2012;5(1):41.PubMedCentralPubMedCrossRef
61.
Pasqualucci L, Neumeister P, Goossens T, Nanjangud G, Chaganti R, Küppers R, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001;412(6844):341–6.PubMedCrossRef
62.
McCune RC, Syrbu SI, Vasef MA. Expression profiling of transcription factors Pax-5, Oct-1, Oct-2, BOB. 1, and PU. 1 in Hodgkin’s and non-Hodgkin’s lymphomas: a comparative study using high throughput tissue microarrays. Mod Pathol. 2006;19.
63.
García-Cosío M, Santón A, Martín P, Camarasa N, Montalbán C, García JF, et al. Analysis of transcription factor OCT. 1, OCT. 2 and BOB. 1 expression using tissue arrays in classical Hodgkin’s lymphoma. Mod Pathol. 2004;17(12):1531–8.PubMedCrossRef
64.
Theil J, Laumen H, Marafioti T, Hummel M, Lenz G, Wirth T, et al. Defective octamer-dependent transcription is responsible for silenced immunoglobulin transcription in Reed–Sternberg cells. Blood. 2001;97(10):3191–6.PubMedCrossRef
65.
Saki N, Abroun S, Hajizamani S, Rahim F, Shahjahani M. Association of chromosomal translocation and miRNA expression with the pathogenesis of multiple myeloma. Cell J. 2014;16(2):99–110.
66.
Zheng X, Abroun S, Otsuyama K-i, Asaoku H, Kawano MM. Heterogeneous expression of CD32 and CD32-mediated growth suppression in human myeloma cells. Haematologica. 2006;91(7):920–8.PubMed
67.
Borson ND, Lacy MQ, Wettstein PJ. Altered mRNA expression of Pax5 and Blimp-1 in B cells in multiple myeloma. Blood. 2002;100(13):4629–39.PubMedCrossRef
68.
Martins G, Calame K. Regulation and functions of Blimp-1 in T and B lymphocytes. Annu Rev Immunol. 2008;26:133–69.PubMedCrossRef
69.
Torlakovic E, Torlakovic G, Nguyen PL, Brunning RD, Delabie J. The value of anti-pax-5 immunostaining in routinely fixed and paraffin-embedded sections: a novel pan pre-B and B-cell marker. Am J Surg Pathol. 2002;26(10):1343–50.PubMedCrossRef
70.
Morgenstern DA, Hasan F, Gibson S, Winyard P, Sebire NJ, Anderson J. PAX5 Expression in nonhematopoietic tissues reappraisal of previous studies. Am J Clin Pathol. 2010;133(3):407–15.PubMedCrossRef
71.
O’Brien P, Morin P, Ouellette RJ, Robichaud GA. The Pax-5 gene: a pluripotent regulator of B-cell differentiation and cancer disease. Cancer Res. 2011;71(24):7345–50.PubMedCrossRef
72.
Cazzaniga G, Daniotti M, Tosi S, Giudici G, Aloisi A, Pogliani E, et al. The paired box domain gene PAX5 is fused to ETV6/TEL in an acute lymphoblastic leukemia case. Cancer Res. 2001;61(12):4666–70.PubMed
73.
Chisté M, Vrotsos E, Zamora C, Martinez A. Chronic lymphocytic leukemia/small lymphocytic lymphoma involving the aortic valve. Ann Diagn Pathol. 2013;17(3):295–7.PubMedCrossRef
74.
Bharti B, Mishra R. Isoforms of Pax5 and co-regulation of T-and B-cells associated genes influence phenotypic traits of ascetic cells causing Dalton’s lymphoma. Biochimica et Biophysica Acta (BBA)-Mol Cell Res. 2011;1813(12):2071–8.CrossRef
75.
Kim M, Choi JE, She CJ, Hwang SM, Shin HY, Ahn HS, et al. PAX5 deletion is common and concurrently occurs with CDKN2A deletion in B-lineage acute lymphoblastic leukemia. Blood Cells Mol Dis. 2011;47(1):62–6.PubMedCrossRef
76.
Russell LJ, Akasaka T, Majid A, Sugimoto K-j, Karran EL, Nagel I, et al. t (6; 14)(p22; q32): a new recurrent IGH@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood. 2008;111(1):387–391.
Metadata
Title
The role of Pax5 in leukemia: diagnosis and prognosis significance
Authors
Mohammad Shahjahani
Fatemeh Norozi
Ahmad Ahmadzadeh
Saeid Shahrabi
Farzaneh Tavakoli
Ali Amin Asnafi
Najmaldin Saki
Publication date
01-01-2015
Publisher
Springer US
Published in
Medical Oncology / Issue 1/2015
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0360-6

Other articles of this Issue 1/2015

Medical Oncology 1/2015 Go to the issue

Original Paper

Knockdown of CDC2 expression inhibits proliferation, enhances apoptosis, and increases chemosensitivity to temozolomide in glioblastoma cells

Original Paper

Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: is it useful the application in clinical practice? A pilot study

Original Paper

Molecular spectrum of c-KIT and PDGFRA gene mutations in gastro intestinal stromal tumor: determination of frequency, distribution pattern and identification of novel mutations in Indian patients

Original Paper

Expression of caspase-3 predicts prognosis in advanced noncardia gastric cancer

Original Paper

Short hairpin RNA (shRNA) of type 2 interleukin-1 receptor (IL1R2) inhibits the proliferation of human osteosarcoma U-2 OS cells

Original Paper

CrkL regulates SDF-1-induced breast cancer biology through balancing Erk1/2 and PI3K/Akt pathways
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits